ArticleThe clinical respiratory journal2026
Severe HCoV-OC43 Pneumonia in a 25-Year-Old Woman Following Allogeneic Hematopoietic Stem Cell Transplantation.
Article in The clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundWe report the case of a 25-year-old woman with a history of acute lymphoblastic leukemia who developed progressive dyspnea and fever following allogeneic hematopoietic stem cell transplantation. CASE PRESENTATION: Despite broad-spectrum empirical antimicrobial therapy, the patient's clinical condition worsened. Comprehensive diagnostic evaluation revealed human coronavirus OC43 (HCoV-OC43) as the causative pathogen. Histopathological examination of lung tissue confirmed viral pneumonia. Treatment with nirmatrelvir/ritonavir (Paxlovid) was initiated. The patient demonstrated rapid clinical improvement, with complete radiological resolution within 3 months.
conclusionThis case highlights the potential therapeutic role of nirmatrelvir/ritonavir in managing severe HCoV-OC43 pneumonia in patients who are immunocompromised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.